© EQS Newswire
05.11.2024
EVT
LISTED
XETR
Evotec gibt Verkauf von API-Produktionsanlage an Monacum Partners bekannt
News Preview
Evotec veräußert auf API Herstellung fokussierten CDMO-Betrieb in Halle (Westf.) (Evotec DS) an Monacum Partners
Transaktion ist Teil von Evotecs strategischer Optimierung, die eigenen Ressourcen auf Kernwachstumstreiber zu konzentrieren
Neuer Eigentümer verpflichtet sich zum Erhalt und Ausbau des Geschäfts
Hamburg, 05 Nov......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.11.2024
EVT
LISTED
XETR
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
News Preview
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners
Transaction aligns with Evotec’s strategic optimization efforts, concentrating resources on key growth drivers
New ownership committed to maintaining and growing the business
Hamburg, 05 November 2024:
Evotec SE (Frankfur......
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company BOOST Pharma successfully completes pre-IND meeting with FDA and receives second tranche of investment
News Preview
STOCKHOLM, SWEDEN, November 5 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has succesfully completed a pre-IND meeting with the U.S. Food and Drug Administration, FDA, for its cell therapy aiming to treat children with the rare bone disease Osteogenesis Imperfecta (OI). The positiv...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
05.11.2024
COLO B
LISTED
CPH
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24
News Preview
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
05.11.2024
COLO B
LISTED
CPH
Coloplast A/S - Full-Year Financial Results 2023/24
News Preview
2023/24...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
COLO B
LISTED
CPH
Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive Leadership Team
News Preview
Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.11.2024
EVT
LISTED
XETR
Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
News Preview
Evotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum PartnersTransaction aligns with Evotec's strategic optimization efforts, concentrating resources on key growth driversNew ownership committed to maintaining and growing the business HAMBURG, GERMANY / ACCESSWIRE / November 5, 2024 / Evotec SE (Frankfurt St...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
TEM
LISTED
NASDAQ
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended September 30, 2024. The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing that aims to improve h...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
SOBI
LISTED
STO
David Meek is proposed as new Chair of the Board of Directors of Sobi
News Preview
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary General Meeting to be held in December 2024.
STOCKHOLM, Nov. 4, 2024 /PRNewswire/ -- David Meek currently serves as a member of the Board of Directors o...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
SOBI
LISTED
STO
David Meek is proposed as new Chair of the Board of Directors of Sobi
News Preview
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary General Meeting to be held in December 2024.
STOCKHOLM, Nov. 4, 2024 /PRNewswire/ -- David Meek currently serves as a member of the Board of Directors o...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
MURA
LISTED
NASDAQ
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on November 1, the Company granted to five newl...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Nantes, le 4 novembre 2024 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), société intégrée de biotechnologie qui développe des immunothérapies innovantes, en direct ou via des partenariats, pour l’activation et la régulat...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
04.11.2024
ATNM
LISTED
XASE
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
News Preview
- Dr. Almenoff brings more than 25 years of drug development and leadership
experience to the Actinium Board of Directors
- Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee
NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, I...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
NSIS B
LISTED
CPH
Trading by management and close relations of management
News Preview
Announcement released on November 4, 2024 at 10:07:51 CET did not include PDF file....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
NSIS B
LISTED
CPH
Trading by management and close relations of management
News Preview
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2024
FYB
LISTED
XETR
Formycon beantragt Wechsel in den Prime Standard der Frankfurter Wertpapierbörse
News Preview
Pressemitteilung // 04. November 2024
Formycon beantragt Wechsel in den Prime Standard der Frankfurter Wertpapierbörse
Zulassung zum Handel im regulierten Markt (Prime Standard) der Frankfurter Wertpapierbörse wird heute beantragt
Formycon-Aktien werden voraussichtlich ab dem 12. November 2024 im Prime Standard der Frankfurter Wertpapierbörse ge......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2024
FYB
LISTED
XETR
Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
News Preview
Press Release // November 04, 2024
Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
Application for admission to trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange will be submitted today
Trading of Formycon shares on the Prime Standard segment is expected to start on November 12,......
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
News Preview
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2024
QGEN
LISTED
NYSE
QIAGEN erhält FDA-Zulassung für QIAstat-Dx Meningitis/ Enzephalitis-Panel zur Unterstützung der Notfalldiagnostik
News Preview
QIAstat-Dx Meningitis/Enzephalitis-Panel in den USA für den klinischen Einsatz zugelassen, um Diagnosen von Infektionen des zentralen Nervensystems zu unterstützen // Vierte FDA-Zulassung in 2024 markiert Meilenstein bei der erfolgreichen Erweiterung von speziell für die USA entwickelten QIAstat-Dx-Tests // QIAGEN bietet breites Portfolio von FDA-z...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
TEM
LISTED
NASDAQ
Tempus to Report Third Quarter 2024 Financial Results on November 4
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day. The c...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.11.2024
ZEAL
LISTED
CPH
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
News Preview
Press Release – No. 10 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.11.2024
ORNBV
LISTED
HEL
Orion Corporation: Managers’ transactions – Henrik Stenqvist
News Preview
ORION CORPORATION MANAGERS’ TRANSACTIONS 1 NOVEMBER 2024 at 9.45 EET...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
BIOA B
LISTED
STO
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
News Preview
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous autoinjector for weekly maintenan...
Themefolio
Profiler
Peergroup
© PR Newswire
01.11.2024
BIOA B
LISTED
STO
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
News Preview
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous autoinjector for weekly maintenan...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
AMP
LISTED
EURONEXT
Amplifon Hearing Health Care Achieves HITRUST r2 Certification
News Preview
Amplifon Hearing Health Care, the leading independent provider of hearing benefit solutions in the U.S., has earned certified status by HITRUST for information security for its platform and facilities.
The globally recognized HITRUST r2 Certification verifies that Amplifon’s Health Solutions Plus Platform and supporting IT and business processes...
Themefolio
Profiler
Peergroup
© BusinessWire
31.10.2024
HELP
LISTED
NASDAQ
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 202...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
News Preview
CONSHOHOCKEN, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2024 financial results and provides corporate updates....
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
TFX
LISTED
NYSE
Teleflex Announces Quarterly Dividend
News Preview
WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable December 16, 2024, to shareholders of record at the close of business on November 15, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
31.10.2024
TFX
LISTED
NYSE
Teleflex Reports Third Quarter Financial Results and Full Year 2024 Outlook
News Preview
WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 29, 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
BIOA B
LISTED
STO
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
News Preview
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, Spain, and virtually, October 29 to November 1. Three-year data show that lecanemab continues to give incr...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
BIOA B
LISTED
STO
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
News Preview
STOCKHOLM, Oct. 31, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, Spain, and virtually, October 29 to November 1. Three-year data show that lecanemab continues to give incr...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
INDV
LISTED
NASDAQ
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
News Preview
Evidence demonstrates that SUBLOCADE supports long-term recovery from opioid use disorder (OUD) and is effective and safe.Publications highlight the importance of overcoming access barriers to long-acting injectable treatments for OUDRICHMOND, Va., Oct. 30, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Preve...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
SLP
LISTED
NASDAQ
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded grant from the U.S. Food and Drug Administration (FDA), secured in partnership with the University of Strathc...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2024
RXRX
LISTED
NASDAQ
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
News Preview
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2024
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. to Present at UBS Global Healthcare Conference
News Preview
MINNEAPOLIS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the UBS Global Healthcare...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.10.2024
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
News Preview
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Ass...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
LIVN
LISTED
NASDAQ
LivaNova Reports Third-Quarter 2024 Results
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance.
Financial Summary and Highlights(1)
Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year pe...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
HNSA
LISTED
STO
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
News Preview
LUND, Sweden, Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, 'Inflammatory Insights: Advancing Novel Therapeutic...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
HNSA
LISTED
STO
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
News Preview
LUND, Sweden, Oct. 30, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it will attend Truist Securities BioPharma Symposium on November 7 in New York, NY. Hitto Kaufmann, Chief R&D Officer at the Company will participate in a panel discussion entitled, 'Inflammatory Insights: Advancing Novel Therapeutic...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
BIOA B
LISTED
STO
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
News Preview
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials in Alzheimer's Disease (CTAD) congress in Madrid on October 29. Professor Lannfe...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
BIOA B
LISTED
STO
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
News Preview
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic's co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials in Alzheimer's Disease (CTAD) congress in Madrid on October 29. Professor Lannfe...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
SECT_B
LISTED
STO
Largest university hospital in Belgium chooses digital pathology from Sectra to further enhance cancer diagnostics
News Preview
LINKÖPING, Sweden, Oct. 30, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed an enterprise imaging contract with Belgium's largest university hospital, UZ Leuven. The healthcare provider will utilize the module for digital pathology, providing pathologists with a digital solution desi...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
SOBI
LISTED
STO
New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
News Preview
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still's disease (AOSD) who had an inadequate response to high-dose glucocort...
Themefolio
Profiler
Peergroup
© PR Newswire
30.10.2024
SOBI
LISTED
STO
New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
News Preview
STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) in Still's disease, including systemic juvenile idiopathic arthritis (sJIA) and adult-onset still's disease (AOSD) who had an inadequate response to high-dose glucocort...
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2024
EVT
LISTED
XETR
Bekanntgabe der Ergebnisse für die ersten neun Monate 2024 am 06. November 2024
News Preview
Hamburg, 30. Oktober 2024:
Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) veröffentlicht am Mittwoch, 06. November 2024, ihren Bericht für die ersten neun Monate 2024.
In einer Telefonkonferenz in englischer Sprache werden die Ergebnisse der ersten neun Monate präsentiert und erläutert. Außerdem wird......
Themefolio
Profiler
Peergroup
© EQS Newswire
30.10.2024
EVT
LISTED
XETR
Evotec SE to announce results for the first nine months 2024 on 06 November 2024
News Preview
Hamburg, Germany, 30 October 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.
The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing ......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.10.2024
EVT
LISTED
XETR
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024
News Preview
HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.10.2024
PHARM
LISTED
EURONEXT
First Berlin Equity Research GmbH: Pharming Group NV | Rating: Buy
News Preview
Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
29.10.2024 / 14:51 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclu......
Themefolio
Profiler
Peergroup
© PR Newswire
29.10.2024
CYRX
LISTED
NASDAQ
Cryoport to Report Third Quarter 2024 Financial Results on November 7, 2024
News Preview
NASHVILLE, Tenn., Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2024 on Thursday, November 7, 2024 after U.S. markets close....
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2024
ZLAB
LISTED
NASDAQ
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of KarXT (xanomeline and trospium chloride) in China. Consistent with previous global studies, the registrational bridging trial met its primary endpoint, with KarXT demonstrating a st...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
News Preview
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skye’s new Chairman of the Board, effective October 25, 2024. Mr. Gr...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.10.2024
ORNBV
LISTED
HEL
Orion Group Interim Report January–September 2024
News Preview
ORION CORPORATION INTERIM REPORT 1–9/2024 29 OCTOBER 2024 at 12:00 EET...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.10.2024
AUTL
LISTED
NASDAQ
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
News Preview
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024...
Themefolio
Profiler
Peergroup
© PR Newswire
27.10.2024
SOBI
LISTED
STO
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
News Preview
Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favoured treatment with pegcetacoplan, including: - Stabilised eGFR, a key measure of kidney function- 71% of patients achieved zero C3c staining intensity, indicating clearance of C3c depositsR...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2024
ORX
LISTED
STO
Orexo initiates new study of OX640 in participants with allergic rhinitis
News Preview
OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo´s proprietary drug delivery platform, AmorphOX®, and has demonstrated positive data in a phase 1 clinical study in healthy volunteers.The new study will investigate the performance of OX...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2024
ORX
LISTED
STO
Orexo initiates new study of OX640 in participants with allergic rhinitis
News Preview
OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo´s proprietary drug delivery platform, AmorphOX®, and has demonstrated positive data in a phase 1 clinical study in healthy volunteers.The new study will investigate the performance of OX...
Themefolio
Profiler
Peergroup
© PR Newswire
25.10.2024
SOBI
LISTED
STO
Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call
News Preview
STOCKHOLM, Oct. 25, 2024 /PRNewswire/ --
VALIANT Phase 3 results after presentation at ASN
Investors, analysts, and members of the media are invited to a conference call on Tuesday, October 29th, at 12:00 CET, 11:00 GMT, and 07:00 EDT. The call will include a presentation of results and insights from management and Professor Fadi Fakhouri follow...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2024
ORNBV
LISTED
HEL
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION24 OCTOBER 2024 at 19.50 EEST...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.10.2024
ORY
LISTED
BME
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024
News Preview
MADRID and CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the nine months ending September 30, 2024 and provided a corpor...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
TEM
LISTED
NASDAQ
Tempus to Report Third Quarter 2024 Financial Results on November 7
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day.
Th...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
